Utility of 18 Fludeoxyglucose in Preoperative Positon-Emission Tomography-Computed Tomography (PET-CT) in the Early Diagnosis of Exocrine Pancreatic Cancer: A Study of 139 Resected Cases

Navarro, 2010, Recomendaciones para el diagnóstico, estadificación y tratamiento del cáncer de páncreas (parte I), Med Clin (Barc), 134, 643, 10.1016/j.medcli.2009.12.014 Ducreux, 2015, Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v56, 10.1093/annonc/mdv295 Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254 Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, 74, 2913, 10.1158/0008-5472.CAN-14-0155 Navarro, 2010, Recomendaciones para el diagnóstico, estadificación y tratamiento del cáncer de páncreas (parte II), Med Clin (Barc), 134, 692, 10.1016/j.medcli.2010.01.006 Vincent, 2011, Pancreatic cancer, Lancet, 378, 607, 10.1016/S0140-6736(10)62307-0 Bilimoria, 2007, National failure to operate on early stage pancreatic cancer, Ann Surg, 246, 173, 10.1097/SLA.0b013e3180691579 Hidalgo, 2010, Pancreatic cancer, N Engl J Med, 362, 1605, 10.1056/NEJMra0901557 Garrido-Laguna, 2015, Pancreatic cancer: from state-of-the-art treatments to promising novel therapies, Nat Rev Clin Oncol, 12, 319, 10.1038/nrclinonc.2015.53 Hruban, 2000, Progression model for pancreatic cancer, Clin Cancer Res, 6, 2969 Hruban, 2007, Clinical importance of precursor lesions in the pancreas, J Hepatobiliary Pancreat Surg, 14, 255, 10.1007/s00534-006-1170-9 Wilde, 2011, Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm, Diag Histopathol, 18, 17, 10.1016/j.mpdhp.2011.10.012 Brosens, 2015, Pancreatic adenocarcinoma pathology: changing landscape, J Gastrointest Oncol, 6, 358 Chari, 2015, Early detection of sporadic pancreatic cancer. Summative review, Pancreas, 44, 693, 10.1097/MPA.0000000000000368 Lu, 1997, Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT, Am J Roentgenol, 168, 1439, 10.2214/ajr.168.6.9168704 Heinrich, 2005, Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness, Ann Surg, 242, 235, 10.1097/01.sla.0000172095.97787.84 Pakzad, 2006, The role of positron emission tomography in the management of pancreatic cancer, Semin Nucl Med, 36, 248, 10.1053/j.semnuclmed.2006.03.005 Wakabayashi, 2008, Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer, World J Gastroenterol, 14, 64, 10.3748/wjg.14.64 Strobel, 2008, Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer, J Nucl Med, 49, 1408, 10.2967/jnumed.108.051466 Kauhanen, 2009, A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer, Ann Surg, 250, 957, 10.1097/SLA.0b013e3181b2fafa Altamirano Ley, 2005, Tomografía por emisión de positrones PET. Fundamentos e indicaciones, Act Med, 3, 179 Fendrich, 2011, Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer, Neoplasia, 13, 180, 10.1593/neo.10956 2009 2009 Ruf, 2005, Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI, Pancreatology, 5, 266, 10.1159/000085281 Shrikhande, 2012, Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature, HPB (Oxford), 14, 658, 10.1111/j.1477-2574.2012.00508.x Santhosh, 2013, Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics, J Gastroenterol Hepatol, 28, 255, 10.1111/jgh.12068 Rijkers, 2014, Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cáncer: a meta-analysis, Eur J Surg Oncol, 40, 794, 10.1016/j.ejso.2014.03.016 Wang, 2014, The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma, Hepatogastroenterology, 61, 2102 Burge, 2015, A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers, HPB, 17, 624, 10.1111/hpb.12418 Chirindel, 2015, Prognostic Value of FDG PET/CT-derived parameters in pancreatic adenocarcinoma at initial PET/CT staging, AJR, 204, 1093, 10.2214/AJR.14.13156 Raman, 2015, Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation, Sem Oncol, 42, 40, 10.1053/j.seminoncol.2014.12.005 Zhang, 2015, Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer, W J Gastroenterol, 21, 2988, 10.3748/wjg.v21.i10.2988 Kawada, 2015, Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors, Pancreas, 44, 655, 10.1097/MPA.0000000000000313